Twitxy Saved

Estefania Gauto Mariotti, MD

@stefigm

BMT/plasma cell dyscrasias advanced fellowship. My views are my own.
Rochester, Minnesota Joined March 2011
485 Following 246 Followers 322 Posts

Latest posts 5

Estefania Gauto Mariotti, MD @stefigm
Fixed duration maintenance in standard-risk NDMM not undergoing up-front autologous transplant. Practice changing! Amazing Mayo experts I had the pleasure to learn from 😇
Vincent Rajkumar Verified account @VincentRK Jul 15
Just out!! In @NEJM - Our randomized trial in myeloma (ENDURANCE trial) shows limited duration of lenalidomide maintenance is just as good as indefinite therapy, with less side effects!!! @eaonc @theNCI

Implications are HUGE. This is a drug we spends billions on each year:

-Less side effects
-Less second cancers
-Similar overall survival
-Less cost
@myelomaMD @Myeloma_Doc @SagarLonialMD

National NCI funded trial led by @eaonc and joined by @ALLIANCE_org & @SWOG

nejm.org/doi/full/10.10…
View quoted post on X
0 replies 2 reposts 5 likes 1.2K views View on X
Estefania Gauto Mariotti, MD @stefigm
rdcu.be/fuSKW hot off the press! A wonderful way to wrap up my Dysproteinemia year at Mayo learning from world experts in myeloma. So grateful to all my coauthors, and a special thank you to Dr @ZanwarSaurabh and Dr Kumar @myelomaMD for their mentorship!
Saurabh Zanwar Verified account @ZanwarSaurabh Jul 21
As response-adapted myeloma trials increasingly use early MRD negativity to guide treatment randomization and possible de-escalation, a key question is:

Does MRD negativity after ASCT overcome the adverse biology of high-risk cytogenetics?

Our latest @LeukemiaJnl study suggests not necessarily.

Take-home message:
👉 MRD negativity after ASCT does not fully overcome the adverse prognostic impact of high-risk cytogenetics.

nature.com/articles/s4137…
View quoted post on X
Estefania Gauto Mariotti, MD @stefigm
Excellent work @Kennethjclim
Hamza Hashmi Verified account @hhashmi87 Apr 24
This paper is a great read and addresses an area of uncertainty in #Myeloma

Should we consider treating SBPmm with HR CG (del17p, 1q) like Myeloma? @Rfonsi1 @RahulBanerjeeMD @VincentRK @brandon_imber

A multi-center study of progression-risk and outcomes in solitary bone plasmacytoma with and without marrow involvement ashpublications.org/bloodadvances/…
View quoted post on X